BMY monthly performance report
Monthly BMY research: returns, drawdown, relative strength, seasonality, and key stats.
BMY monthly report
—
Key takeaways
- Bristol Myers Squibb (BMY) closed August 2026 at $63.63, down 2.57% for the month and +38.78% over the trailing 12 months.
- Year-to-date, BMY is +17.96%, outperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +13.99% versus its 200-day moving average ($55.82), a bullish technical signal.
- Over the past three years, BMY has underperformed the S&P 500 by −67.09%, with a relative strength index reading of 61.6.
- Win rate over the trailing 39 months stands at 51.3% — 20 positive months versus 19 negative months.
Bristol Myers Squibb ended August 2026 at $63.63, posting a monthly return of −2.57%. The S&P 500 returned +3.05% over the same window, leaving relative performance at −5.62%.
The current quarter stands at +11.15% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +13.99% versus the 200-day moving average ($55.82).
Year-to-date, BMY is +17.96% against SPY +12.89%, a gap of +5.08%. The stock is currently −4.04% below its 52-week high, with maximum 3-year drawdown at −36.90%.
| Period | BMY | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −3.43% | −0.20% | −3.23% |
| 1 Week | +0.05% | +3.90% | −3.86% |
| 1 Month | −2.57% | +3.05% | −5.62% |
| 3 Months | +5.02% | +7.11% | −2.10% |
| 6 Months |